Correlation Between PDS Biotechnology and Checkpoint Therapeutics

Can any of the company-specific risk be diversified away by investing in both PDS Biotechnology and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PDS Biotechnology and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PDS Biotechnology Corp and Checkpoint Therapeutics, you can compare the effects of market volatilities on PDS Biotechnology and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PDS Biotechnology with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of PDS Biotechnology and Checkpoint Therapeutics.

Diversification Opportunities for PDS Biotechnology and Checkpoint Therapeutics

-0.54

Correlation Coefficient

PDS Biotechnology  Checkpoint Therapeutics

Excellent diversification

The 3 months correlation between PDS and Checkpoint is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding PDS Biotechnology Corp and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and PDS Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PDS Biotechnology Corp are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of PDS Biotechnology i.e., PDS Biotechnology and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between PDS Biotechnology and Checkpoint Therapeutics

Given the investment horizon of 90 days PDS Biotechnology Corp is expected to under-perform the Checkpoint Therapeutics. In addition to that, PDS Biotechnology is 1.21 times more volatile than Checkpoint Therapeutics. It trades about -0.1 of its total potential returns per unit of risk. Checkpoint Therapeutics is currently generating about 0.25 per unit of volatility. If you would invest  235.00  in Checkpoint Therapeutics on August 30, 2024 and sell it today you would earn a total of  193.00  from holding Checkpoint Therapeutics or generate 82.13% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

PDS Biotechnology Corp  vs.  Checkpoint Therapeutics

PDS Biotechnology Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Checkpoint Therapeutics

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with PDS Biotechnology and Checkpoint Therapeutics

The main advantage of trading using opposite PDS Biotechnology and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PDS Biotechnology position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.

The idea behind PDS Biotechnology Corp and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.